| What are the risks and the benefits of current and emerging weight-loss medications? | |
| | |
MedLine Citation:
|
PMID: 19793507 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Obesity is epidemic; new medications and therapeutic options are urgently needed to reduce the associated health care burden. The initial clinical strategy for weight loss is lifestyle modification involving a combination of diet, exercise, and behavior change. However, it is difficult for many to achieve and maintain weight loss solely through this approach. Only two drugs, orlistat and sibutramine, have been approved by the US Food and Drug Administration (FDA) to treat obesity long term, and both medications have undesirable side effects, leaving an enormous unmet need for efficacious and safe therapy for obesity. Other medications with weight-loss effects have been approved by the FDA for short-term treatment of obesity or for disorders other than obesity, but these also have potential adverse effects. This article discusses the perceived benefits and risks of these approved medications along with emerging drugs that have shown weight-loss effects. |
| | |
Authors:
|
Jamie R Robinson; Kevin D Niswender |
Related Documents
:
|
8726437 - The evaluation and image-guided surgical treatment of the patient with a medically intr... 8439937 - Drowning deaths in people with epilepsy. 2252367 - Failure of nine-month phenobarbital administration to reverse amygdaloid-kindled seizur... 15564057 - Neurofeedback treatment of epilepsy. 8683527 - Severe small airways disease resistant to medical treatment in a child with cystic fibr... 10272897 - Florida legislature passes medical malpractice law. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current diabetes reports Volume: 9 ISSN: 1539-0829 ISO Abbreviation: Curr. Diab. Rep. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-01 Completed Date: 2010-01-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101093791 Medline TA: Curr Diab Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 368-75 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, TN 37232, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Obesity Agents
/
adverse effects*,
pharmacology,
therapeutic use* Cyclobutanes / adverse effects, therapeutic use Humans Lactones / adverse effects, therapeutic use Obesity / drug therapy* Weight Loss / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Obesity Agents; 0/Cyclobutanes; 0/Lactones; 106650-56-0/sibutramine; 96829-58-2/orlistat |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New therapies for diabesity.
Next Document: Use of the glycemic index for weight loss and glycemic control: a review of recent evidence.